Human induced pluripotent stem (iPS) cells and cells differentiated from iPS cells have widely been used for in vivo models human disease progression. Jason Meyer, of Indiana University Purdue University Indianapolis, uses iPS cell-derived models to study retinogenesis and retinal disease. Two recent papers from his lab highlight the benefits of using Stemgent’s RNA reprogramming technology to enable robust differentiation of iPS cells to the retinal lineage (1, 2). RNA reprogramming technology was chosen in order for these studies to ensure that no vestiges of the reprogramming vectors were retained by the cells or integrated into the genome.
Most popular posts
- HeLa cells: Origin of this important cell line in life science research
- From RUO to IVD - the acronym guide to reagents' intended use
- Differentiate between Apoptosis, Necroptosis, Autophagy & Ferroptosis
- Differentiate between K48- and K63-specific Ubiquitination
- How to choose the perfect buffer to get a pure, stabilised, functional protein